Literature DB >> 17028294

Molecular and pathologic aspects of endometrial carcinogenesis.

Jonathan L Hecht1, George L Mutter.   

Abstract

Endometrial cancer is the most common gynecological malignancy, with 41,000 new cases projected in the United States for 2006. Two different clinicopathologic subtypes are recognized: the estrogen-related (type I, endometrioid) and the non-estrogen-related types (type II, nonendometrioid such as papillary serous and clear cell). The morphologic differences in these cancers are mirrored in their molecular genetic profile with type I showing defects in DNA-mismatch repair and mutations in PTEN, K-ras, and beta-catenin, and type II showing aneuploidy and p53 mutations. This article reviews the genetic aspects of endometrial carcinogenesis and progression. We will define the precursor lesion of type I endometrioid cancer and the role of genetics and estrogen in its progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17028294     DOI: 10.1200/JCO.2006.06.7173

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  151 in total

1.  High levels of Nrf2 determine chemoresistance in type II endometrial cancer.

Authors:  Tao Jiang; Ning Chen; Fei Zhao; Xiao-Jun Wang; Beihua Kong; Wenxin Zheng; Donna D Zhang
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  "Surface epithelial changes" in uterine endometrioid carcinoma mimicking micropapillary serous borderline tumor of ovary: report of two cases and review of the literature.

Authors:  Kamaljeet Singh; Rochelle A Simon; Cunxian Zhang; M Ruhul Quddus
Journal:  Diagn Pathol       Date:  2011-01-27       Impact factor: 2.644

Review 3.  Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment.

Authors:  A S Felix; J Weissfeld; R Edwards; F Linkov
Journal:  Eur J Gynaecol Oncol       Date:  2010       Impact factor: 0.196

4.  Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.

Authors:  Victoria L Bae-Jump; Chunxiao Zhou; John F Boggess; Young E Whang; Lisa Barroilhet; Paola A Gehrig
Journal:  Gynecol Oncol       Date:  2010-09-21       Impact factor: 5.482

5.  Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: a conserved regulatory mechanism important in tumorigenesis?

Authors:  Yevgeniya J Ioffe; Katherine B Chiappinelli; David G Mutch; Israel Zighelboim; Paul J Goodfellow
Journal:  Gynecol Oncol       Date:  2011-10-15       Impact factor: 5.482

Review 6.  Non-Coding RNAs in Endometrial Physiopathology.

Authors:  Alessandro La Ferlita; Rosalia Battaglia; Francesca Andronico; Salvatore Caruso; Antonio Cianci; Michele Purrello; Cinzia Di Pietro
Journal:  Int J Mol Sci       Date:  2018-07-20       Impact factor: 5.923

Review 7.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

8.  Association Between Single Nucleotide Polymorphism +276G > T (rs1501299) in ADIPOQ and Endometrial Cancer.

Authors:  Jan Bieńkiewicz; Beata Smolarz; Andrzej Malinowski
Journal:  Pathol Oncol Res       Date:  2015-09-19       Impact factor: 3.201

9.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

Review 10.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.